



NLPDP Biosimilars Initiative

Switching Patients from
Biologics to Biosimilars

The Newfoundland and Labrador Prescription Drug Program (NLPDP) will be transitioning coverage for the following biologic drugs to their biosimilar versions:

- **Copaxone** (glatiramer)
- **Enbrel** (etanercept)
- **Humalog** (insulin lispro)
- **Humira** (adalimumab)
- **Lantus** (insulin glargine)
- **Lovenox** (enoxaparin)
- **NovoRapid** (insulin aspart)
- **Remicade** (infliximab)
- **Rituxan** (rituximab)

On **March 31, 2024**, coverage for the above biologics will cease. To maintain uninterrupted coverage, patients need to be transitioned to a biosimilar, barring any necessary exemptions (i.e., unconfirmed compatibility with insulin pumps).

Pharmacies can claim a Special Service Fee for a patient who is transitioning from a biologic insulin listed above. The claim can only be made if the pharmacist prescribes the biosimilar insulin, and the fee is submitted with the first dispense.

Biosimilar Insulin Drug Folders

Table 1. Biosimilar insulins under the Biosimilar Initiative.

DIN	Generic Name	Trade Name	Strength	Originator Biologic
2444844	INSULIN GLARGINE	BASAGLAR	100U/mL	LANTUS
2444852		BASAGLAR		
2461528		BASAGLAR (KWIKPEN)		
2526441		SEMGLEE		
2520974	INSULIN ASPART	KIRSTY	100U/mL	NOVORAPID
2506564		TRURAPI		
2506572		TRURAPI		
2469871	INSULIN LISPRO	ADMELOG SOLOSTAR	100U/mL	HUMALOG
2469898		ADMELOG		
2469901		ADMELOG		



Submitting the Biosimilar Insulin Special Service Fee

The Special Service Fee must be manually entered in the first claim for the biosimilar insulin. The drug cost, markup, and dispensing fee are to be submitted as per usual process.

To submit the Special Service Fee for a biosimilar insulin prescription:

1. Create a new prescription.
2. Enter the following information in the **New Prescription** window:

- **Patient**
- **Drug** = indicated in [Table 1](#)
- **Doctor** = pharmacist



NOTE: The pharmacist must be the prescriber. Otherwise, the Special Service Fee cannot be claimed.

- **Qty Auth** = same as the insulin biologic prescription
 - **Qty** = same as the insulin biologic prescription
 - **SIG**
 - **Days Supl** = same as the insulin biologic prescription
3. Select **Process Now**. Rx Detail opens.
 4. Select the **Third Party** tab.
 5. In the **Special Srv Fee** field, enter 20.00.

Rx: New	Extended	EHR	Third Party	Notes
Claim: 1 of 2 Incomplete	TP: FS	Special Auth #:		
DIN/PIN: 2444844	INSULIN GLARGINE	Special Services:		
Patient: BISHOP, ISAF		Special Srv Fee: 20.00	TP Qty: 15.0	
Pharmacist: TM	Alternative DIN: 2444844	Product Selection:		

6. Select **Fill**.

Additional Resources

- [NLPDP Biosimilar Initiative – Health and Community Services](#)
- [Insulin product and pump compatibility claims: Regulatory notice](#)
- [NLPDP Bulletins](#)

